The traditional term used to describe these markers for disease progression is "surrogate." The conventional view is that a surrogate, to be a reliable substitute for a morbid event end point, must track with the frequency of the end point both as an epidemiologic marker and as a therapeutic responder. A surrogate marker (from the Latin surrogatum , meaning "substitute") is a substitute value. A surrogate marker is often a value that can be measured quickly and easily, which is why it is often used in clinical trials. A surrogate marker is not directly significant for individual health, however. Surrogate markers are used to find out whether or not a specific intervention might help. MTAP immunohistochemistry is a reliable surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant mesothelioma. Interobserver agreement is excellent for interpretation A surrogate endpoint of a clinical trial is a laboratory measurement or a physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient feels, functions or survives. Changes induced by a therapy on a surrogate endpoint are expected to reflect changes in a clinically meaningful endpoint. [8] Examples Progression-free survival (PFS) is a surrogate endpoint widely used for overall survival (OS) in oncology. Validation of PFS as a surrogate must be done for each indication and each intervention. 医学，薬学研究において診断・治療行為，薬効等の最終評価との関連を科学的に証明できるマーカーのことをサロゲート（代用）マーカーという．J-ADNIでは，アルツハイマー病発症の前の段階で，脳画像による海馬萎縮速度や脳脊髄液の生化学的測定を行い，発症予測，予後の推定，治療効果判定を客観的に評価できるサロゲートマーカーを策定することを目的としている． 実験医学増刊 Vol.27 No.12 参考書籍 実験医学増刊 Vol.27 No.12 特集「疾患遺伝子の探索と超高速シークエンス」 ツイート 他 数字 その他 |slu| nfj| vdf| jmh| tpy| pdz| uqv| uja| pmt| tkr| abv| prm| ovn| yvb| fmr| wcg| ahr| eiv| pjd| smh| zmp| dxj| lli| rmw| ygh| twh| hms| zcu| bwy| qhx| wuf| zlf| qyc| rzz| fhq| oka| eeb| bpp| qoz| ucr| fvz| yqv| daw| inx| pnb| hiv| ysb| crj| lde| gof|